Skip to Main Content

A glaucoma drug developed by Aerie Pharmaceuticals (AERI) is currently under review by FDA regulators at the agency’s Rockville, Md., campus, but the decision to approve or reject more likely hinges on the rehabilitation of a dysfunctional manufacturing facility located 900 miles to the south in Tampa, Fla.

Time and circumstances don’t work in Aerie’s favor. The manufacturing facility where Aerie’s drug Rhopressa is made is owned by Bausch & Lomb, a unit of troubled specialty pharmaceuticals firm Valeant Pharmaceuticals (VRX). The plant has a long history of FDA quality control violations Bausch & Lomb can’t seem to fix.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED